Women With High-Risk Early Breast Cancer Lived Longer After Adding Abemaciclib

CATEGORY: WOMEN’S HEALTH

Two years of the targeted pill abemaciclib, added to standard hormone therapy, lowered the relative risk of death by 15.8% in high-risk early breast cancer, in the final survival results of a 5,637-patient randomized trial.¹ That relative figure compares death rates between the two groups across the whole trial. It measures something different from the gap at any single moment. At seven years, 86.8% of patients given the drug were alive against 85.0% without it, and 77.4% versus 70.9% were still free of invasive cancer. This is the first time a drug of this widely used class has been shown to help patients treated for early disease live longer rather than only relapse less.

The Commonest Breast Cancer, in Its Riskiest Form

Enrollment was limited to hormone receptor-positive, HER2-negative breast cancer, the type fueled by estrogen. That type accounts for roughly two of every three breast cancer diagnoses. Every patient also carried features that make relapse likelier, such as spread to several lymph nodes. Standard care after surgery is years of hormone therapy, also called endocrine therapy, which starves the cancer of estrogen. Abemaciclib comes at the problem from a second direction. It blocks CDK4 and CDK6, two proteins that act like an accelerator pedal for cell division, so cancer cells left behind after surgery have a harder time multiplying.

Two Years of Pills, Six and a Half Years of Counting

A randomization program sorted all 5,637 patients into one of two arms: hormone therapy alone for at least five years, or that same therapy with abemaciclib added for the first two. Recurrence and death take their time, so the answer here depended on long follow-up. Patients were tracked for a median of 76.2 months, with recurrences and deaths recorded throughout.¹ That is nearly six and a half years.

Fewer Deaths, and Fewer Cancers That Had Spread

At the final analysis, 301 patients in the abemaciclib group had died against 360 on hormone therapy alone. That is where the 15.8% lower relative risk of death comes from, drawn from death rates across the whole trial rather than from the seven-year percentages. Those percentages show a smaller absolute gap, 86.8% against 85.0%. The gap in staying free of invasive cancer was wider: 77.4% versus 70.9%. Fewer patients on abemaciclib were living with metastatic disease, cancer that has spread to other organs and can no longer be cured, at 6.4% versus 9.4%.¹ The drug’s known side effects were mainly diarrhea and fatigue during the two treatment years. No delayed toxicity turned up afterward.

The Benefit Belongs to One Drug, Not the Family

A related medicine, ribociclib, also lowered recurrence risk when it was tested the same way in more than 5,000 patients with early breast cancer.² A third drug of the same class did not. Palbociclib went through a near-identical trial of 5,761 patients and showed no benefit at all, with invasive disease-free survival of 84.2% versus 84.5%.³ The survival advantage is a property of this particular drug and its trial, not something the class earned as a group.

Key Takeaways

• Two years of abemaciclib on top of hormone therapy after surgery was linked to a 15.8% lower relative risk of death among 5,637 patients with high-risk, hormone receptor-positive early breast cancer: 301 deaths against 360, and 86.8% versus 85.0% alive at seven years. The relative and absolute figures measure different things, which is why their sizes differ so much.
• Recurrence showed the larger difference. At seven years, 77.4% versus 70.9% remained free of invasive cancer, and fewer patients were living with incurable metastatic disease.
• The absolute survival difference at seven years came to under two percentage points, and the finding applies to the high-risk early disease that was studied.
• The effect is drug-specific: ribociclib also reduced recurrences, while palbociclib, of the same class, showed none.

References

1. Johnston S, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Annals of Oncology. 2026;37(2):155–165. link
2. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine. 2024;390(12):1080–1091. link
3. Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology. 2022;40(3):282–293. link